Predictive and Prognostic Roles of Ribonucleotide Reductase M1 in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-analysis

Zhang, Xiong; Jin, Fen-Shu; Zhang, Li-Guo; Chen, Rui-Xue; Zhao, Jin-Hui; Wang, Yan-Nan; Wang, En-Fu; Jiang, Zhen-Dong

추천

검색

자료유형: 학술저널

저자정보: Zhang, Xiong (Department of Laboratory Medicine, Hubei Wuchang Hospital) Jin, Fen-Shu (Department of Laboratory Medicine, Hubei Wuchang Hospital) Zhang, Li-Guo (Department of Laboratory Medicine, Hubei Wuchang Hospital) Chen, Rui-Xue (Department of Laboratory Medicine, Hubei Wuchang Hospital) Zhao, Jin-Hui (Department of Laboratory Medicine, Hubei Wuchang Hospital) Wang, Yan-Nan (Department of Laboratory Medicine, Hubei Wuchang Hospital) Wang, En-Fu (Department of Laboratory Medicine, Hubei Wuchang Hospital) Jiang, Zhen-Dong (Department of Laboratory Medicine, Hubei Wuchang Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제7호

발행연도: 2013.1

수록면: 4,261 - 4,265 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Increasing scientific evidence suggests that ribonucleotide reductase M1 (RRM1) may be a powerful predictor of survival in patients with pancreatic cancer treated with adjuvant gemcitabine-based chemotherapy after operative resection, but many existing studies have yielded inconclusive results. This meta-analysis aimed to assess the prognostic role of RRM1 in predicting survival in patients with pancreatic cancer treated with gemcitabine. An extensive literature search for relevant studies was conducted on PubMed, Embase, Web of Science, Cochrane Library, and CBM databases from their inception through May 1st, 2013. This meta-analysis was performed using the STATA 12.0 software and crude hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Eight clinical studies were included in this meta-analysis with a total of 665 pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy, including 373 patients in the high RRM1 expression group and 292 patients in the low RRM1 expression group. Our meta-analysis revealed that high RRM1 expression was associated with improved overall survival (OS) of pancreatic cancer patients (HR=1.56, 95%CI=0.95-2.17, P<0.001). High RRM1 expression also was linked to longer disease-free survival (DFS) than low RRM1 expression (HR=1.37, 95%CI=0.25-2.48, P=0.016). In conclusion, our meta-analysis suggests that high RRM1 expression may be associated with improved OS and DFS of pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy. Detection of RRM1 expression may be a promising biomarker for gemcitabine response and prognosis in pancreatic cancer patients.

#Pancreatic cancer #gemcitabine #ribonucleotide reductase M1 #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요